A Multi-center, Retrospective, Study on Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer

Status: Recruiting

Location: See location...

Intervention Type: Other

Study Type: Observational

SUMMARY

This study retrospectively analyzes the clinical data of HER2-low breast cancer (IHC 1+/2+ and FISH-negative) patients treated with sequential antibody-drug conjugates (ADCs). Key variables include patient demographics, tumor characteristics, ADC regimens (e.g., trastuzumab deruxtecan, sacituzumab govitecan), treatment sequencing, survival outcomes, and safety profiles. Genomic data (e.g., HER2 expression dynamics, TROP2 levels) are integrated to explore resistance mechanisms and prognostic biomarkers.mechanisms. This study aims to investigate the efficacy of different ADC sequential regimens in HER2-low breast cancer patients.

Eligibility

Participation Requirements

Sex: All

Healthy Volunteers: f

View:

• Diagnosed with HER2-low breast cancer, defined as immunohistochemistry (IHC) score of 1+ or IHC score of 2+ with negative in situ hybridization (FISH-negative)

• Received sequential administration of two or more ADCs

• Complete data for patient's character, laboratory and imaging test, treatment and follow-up are available.

Locations

Other Locations

China

Sun yat-sen University Cancer

RECRUITING

Guangzhou

Contact Information

Primary

Yang Yalan, Bachelor

yangylan7@mail2.sysu.edu.cn

+8613826282096

Time Frame

Start Date: 2020-01-01

Estimated Completion Date: 2026-01

Participants

Target number of participants: 700

Treatments

First-line Trastuzumab Deruxtecan → Second-line Sacituzumab Govitecan

First-line Sacituzumab Govitecan → Second-line Trastuzumab Deruxtecan

First-line RC48 → Second-line Trastuzumab Deruxtecan

First-line Trastuzumab Deruxtecan → Second-line RC48

First-line SKB264 → Second-line Trastuzumab Deruxtecan

First-line Trastuzumab Emtansine → Second-line TQB2102

First-line TQB2102 → Second-line Trastuzumab Deruxtecan

First-line RC48 → Second-line TQB2102

Related Therapeutic Areas

Breast Cancer

Similar Clinical Trials

View All

A Multi-center, Retrospective, Study on Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer

Similar Clinical Trials

Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Phase II Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

Phase II Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

A Multi-center Prospective Observational Study to Assess the Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

A Multi-center Prospective Observational Study to Assess the Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)